Norwegian version of this page

Prostate Cancer

The overall objective of the research group is to foster research that can contribute to more knowledge about causes and development of prostate cancer, and thus lead to better diagnostics and treatment of the disease.

About the group

The Research group of prostate cancer consists of urologists and oncologists (main members) and physicians and scientists from other departments and institutes (associated members), engaged in prostate cancer research at Oslo University Hospital (OUH).

Main topic of clinical research is new diagnostic methods, outcomes studies and Quality of Life studies after primary treatment and salvage treatment of prostate cancer. Another important topic is studies of new diagnostic methods and focal treatment of prostate cancer.

The main aims for our translational research are detection and validation of new putative biomarkers in tumor tissue, blood and urine.

This effort focuses on achieving a more personalized treatment of patients, in order to reduce overdiagnosis and overtreatment of prostate cancer, but also to improve diagnosis and treatment of high risk prostate cancer.

The groups long term goals are to:

  • Prepare one new PhD project for a urological resident
  • Prepare clinical- or translational projects directed towards medical students (Forskningslinje) who can apply for grants during one year off from the medical study
  • Improve Registry and Biobank for urological disease

Projects

New projects

  • Last year our group joined the SPCG-17 study:  Prostate Cancer Active Surveillance Trigger Trial (PCASTT), which is about finding trigger factors for repeat biopsies and radical treatment for patients in active surveillance.
  • The sPLND (salvage Pelvic Lymph Node Dissection) study ended (paper in preparation) and was replaced by the STORM study: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases where the main objective is comparing salvage pelvic radiation or not in patients treated with sPLND or stereotactic radiation against suspicious lymph nodes.
  • Biopsy study: Antibiotic prophylaxis or not for transperineal prostate MRI-TRUS fusion biopsy. 
  • Much work was done to get funding for the NeuroSAFE project in collaboration with UCL, London, where the aim is assessing the value of peroperative frozen section analyses of biopsies during RALP. Our efforts was without success, however, we will apply for funding also this year.
  • Our group is collaborating with the Department of oncology, Radiumhospitalet, in their effort to establish a biobank and clinical registry similar to our prostate registry and biobank.  

Ongoing projects

  • The ongoing FARP study, which is a randomized study comparing radical prostatectomy and focal HIFU treatment for localized prostate cancer, recruited many patients during 2019. 
  • The Exosome project (Urinary exosome test for improved prostate cancer management) is still recruiting patients
  • SPCG-15 (Primary radical prostatectomy versus primary radiotherapy for locally advanced prostate cancer: an open randomized clinical trial) is still recruiting patients
  • Our collaboration with Almac Diagnostics, Belfast, is continuing
  • During 2019 there were monthly teleconferences with collaborators in US, Australia and Finland about the Prostate Cancer Biorepository Network (PCBN) located at Johns Hopkins, Baltimore, and sponsored by the Movember foundation. Our group is represented in the board of the PCBN.

Cooperation

National

  • NCMM, UiO, Ian Mills
  • IMBV, UiO, Fahri Saatcioglu
  • Interventional Centre, Rikshospitalet, Ragnhild Marie Undseth
  • Department of Urology, St. Olavs Hospital, Helena Bertilsson, May–Britt Tessem
  • Institute for Cancer Research, OUH, Kristin Tasken, Alicia Llorente
  • Cancer Registry of Norway

International

  • Johns Hopkins School of Medicine, USA
  • Queen University, Belfast, UK
  • Martini Hospital, Hamburg, Germany
  • University College Dublin, Irland
  • University College of London

Selected Publications

  • Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique.  Fosså SD, Beyer B, Dahl AA, Aas K, Eri LM, Kvan E, Falk RS, Graefen M, Huland H, Berge V . Scand J Urol. 2019 Dec;53(6):385-391.

  • Is time from diagnosis to radical prostatectomy associated with oncological outcomes? Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V. World J Urol. 2019 Aug;37(8):1571-1580
  • Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, Sandvig K, Linē A, Llorente A. Mol Cancer. 2017 Oct 5;16(1):156. doi: 10.1186/s12943-017-0726-4.
  • Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB. Br J Cancer. 2017 Nov 21;117(11):1656-1664.
  • Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway. Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD. Urology. 2017 Dec;110:140-147. doi: 10.1016/j.urology.2017.07.048. Epub 2017 Aug 18.
  • Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW, Clarke NW, Kennedy RD. Eur Urol. 2017 Oct;72(4):509-518. doi: 10.1016/j.eururo.2017.03.027. Epub 2017 Apr 10.
  • Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer. Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM. Cancer Immunol Immunother. 2017 Jul;66(7):891-901. doi: 10.1007/s00262-017-1994-y. Epub 2017 Apr 8.
  • Switching from laparoscopic radical prostatectomy to robot assisted laparoscopic prostatectomy: comparing oncological outcomes and complications. Johnson I, Ottosson F, Diep LM, Berg RE, Hoff JR, Wessel N, Eri LM, Berge V. Scand J Urol. 2018 Jan 15:1-6. doi: 10.1080/21681805.2017.1420099. [Epub ahead of print]
  • Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations. Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA. BMC Urol. 2017 Dec 2;17(1):111. doi: 10.1186/s12894-017-0302-7.

 

Published Aug. 10, 2018 10:32 AM - Last modified May 15, 2020 3:05 PM

Contact

Group Leader

Participants

  • Viktor Berge
  • Kirsti Aas
  • Lars Magne Eri
  • Truls E. Bjerklund Johansen
  • Anne Klara Sørbø
  • Bjørn Brennhovd
  • Eduard Baco
  • Eirin Næss Korshavn
  • Fredrik Ottosson
  • Henriette Veiby Holm
  • Jon Reidar Iversen
  • Lars Fredrik Qvigstad
  • Nicolai Wessel
  • Olav Andreas Hopland
  • Reino Heikkilä
  • Rolf Eigil Berg
  • Shivanthe Sivanesan
  • Sigrun Dahl
  • Wolfgang Lilleby
  • Åsmund Nybøen
Detailed list of participants